Saturday, 31 October 2026European Markets

ATLANTIC SAPPHIRE Stock 12.98% Up On Wednesday

Loading stream...

(VIANEWS) - The Market ended the session with ATLANTIC SAPPHIRE (ASA.OL) rising 12.98% to kr0.22 on Wednesday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.91% to kr1,437.67, after three sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

ATLANTIC SAPPHIRE's last close was kr0.19, 99.05% under its 52-week high of kr20.36.

About ATLANTIC SAPPHIRE

Atlantic Sapphire ASA, together with its subsidiaries, engages in the production and sale of land-based salmon in Denmark and the United States. The company was incorporated in 2010 and is headquartered in Vikebukt, Norway.

Earnings Per Share

As for profitability, ATLANTIC SAPPHIRE has a trailing twelve months EPS of kr-3.54.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -24.26%.

Moving Average

ATLANTIC SAPPHIRE's worth is way below its 50-day moving average of kr6.29 and way under its 200-day moving average of kr6.74.

Volume

Today's last reported volume for ATLANTIC SAPPHIRE is 5372180 which is 220.18% above its average volume of 1677820.

Volatility

ATLANTIC SAPPHIRE's last week, last month's, and last quarter's current intraday variation average was a negative 4.66%, a negative 2.30%, and a positive 8.37%.

ATLANTIC SAPPHIRE's highest amplitude of average volatility was 4.66% (last week), 11.31% (last month), and 8.37% (last quarter).

More news about ATLANTIC SAPPHIRE (ASA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com